Cargando…

Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction

BACKGROUND: Warfarin treatment has a narrow therapeutic range, requiring meticulous monitoring and dosage titration. Individual dosage requirement has recently partly been explained by genetic variation of the warfarin metabolizing enzyme CYP2C9 and the Vitamin K-activating enzyme VKORC1. In the WAR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haug, Kari Bente Foss, Sharikabad, Mohammad N, Kringen, Marianne K, Narum, Sigrid, Sjaatil, Stine T, Johansen, Per Wiik, Kierulf, Peter, Seljeflot, Ingebjørg, Arnesen, Harald, Brørs, Odd
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Original Clinical Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440373/ https://www.ncbi.nlm.nih.gov/pubmed/18559094 http://dx.doi.org/10.1186/1477-9560-6-7

Ejemplares similares

Genetic Variation of VKORC1 and CYP4F2 Genes Related to Warfarin Maintenance Dose in Patients with Myocardial Infarction
por: Kringen, Marianne K., et al.
Publicado: (2011)

Mortality among head trauma patients taking preinjury antithrombotic agents: a retrospective cohort analysis from a Level 1 trauma centre
por: Narum, Sigrid, et al.
Publicado: (2016)

Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population
por: Jia, LiQun, et al.
Publicado: (2017)

VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients
por: Park, Sea Mi, et al.
Publicado: (2013)

Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy
por: Poopak, Behzad, et al.
Publicado: (2015)

Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine
por: Ayesh, Basim Mohammad, et al.
Publicado: (2018)

Methylation of CYP1A1 and VKORC1 promoter associated with stable dosage of warfarin in Chinese patients
por: He, Shiwei, et al.
Publicado: (2021)

Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)
por: Grossniklaus, Daurice
Publicado: (2010)

Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis
por: Jorgensen, Andrea L., et al.
Publicado: (2012)

Warfarin Dosing in a Patient with CYP2C9(∗)3(∗)3 and VKORC1-1639 AA Genotypes
por: Johnson, Mark, et al.
Publicado: (2014)

Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy
por: AL-Eitan, Laith N., et al.
Publicado: (2019)

The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population
por: Taşkın, Birce Dilge, et al.
Publicado: (2016)

Determination of Pleiotropic Effect of Warfarin in VKORC1 and CYP2C9 Genotypes in Patients With Heart Valve Replacement
por: Shafique, Huma, et al.
Publicado: (2022)

VKORC1 variants as significant predictors of warfarin dose in Emiratis
por: Al-Mahayri, Zeina N, et al.
Publicado: (2019)

The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
por: Pettersen, Alf-Aage R, et al.
Publicado: (2011)

The Contribution of VKORC1 and CYP2C9 Genetic Polymorphisms and Patients’ Demographic Characteristics with Warfarin Maintenance Doses: A Suggested Warfarin Dosing Algorithm
por: Khaleqsefat, Esmat, et al.
Publicado: (2020)

Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population
por: Hadjipanagi, Despina, et al.
Publicado: (2014)

The effect of the VKORC1 promoter variant on warfarin responsiveness in the Saudi WArfarin Pharmacogenetic (SWAP) cohort
por: Al Ammari, Maha, et al.
Publicado: (2020)

Warfarin/herbal drink interaction: Elevated INR: case report
Publicado: (2021)

A CONTROVERSY: WARFARIN FAILURE IN COVID-19 WITH SUPRATHERAPEUTIC INR
por: Ur Rahman, Saad
Publicado: (2023)

VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People
por: Henderson, Lindsay M., et al.
Publicado: (2019)

Impact of CYP2C9 and VKORC1 Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy
por: AL-Eitan, Laith N., et al.
Publicado: (2018)

A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
por: Takeuchi, Fumihiko, et al.
Publicado: (2009)

Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia
por: Giraldo-Ocampo, Sebastian, et al.
Publicado: (2023)

Predictors for INR-control in a well-managed warfarin treatment setting
por: Björck, Fredrik, et al.
Publicado: (2018)

Association of Warfarin Therapy with APOE and VKORC1 Genes Polymorphism in Iranian Population
por: Rafiee, Sajad, et al.
Publicado: (2017)

Height, VKORC1 1173, and CYP2C9 Genotypes Determine Warfarin Dose for Pediatric Patients with Kawasaki Disease in Southwest China
por: Yang, Dan, et al.
Publicado: (2018)

Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit
por: Biswas, Mansij, et al.
Publicado: (2018)

Optimal INR level for warfarin therapy after mechanical mitral valve replacement
por: Kamthornthanakarn, Itthidet, et al.
Publicado: (2019)

Genetic and Non-Genetic Factors Impact on INR Normalization in Preprocedural Warfarin Management
por: Eljilany, Islam, et al.
Publicado: (2021)

Pillbox Use and INR Stability in a Prospective Cohort of New Warfarin Users
por: Dumas, Stephanie, et al.
Publicado: (2016)

The effect of CYP2C9*2, CYP2C9*3, and VKORC1-1639 G>A polymorphism in patients under warfarin therapy in city of Kermanshah
por: Hosseinkhani, Zohreh, et al.
Publicado: (2018)

Polymorphisms of CYP2C9*2, CYP2C9*3 and VKORC1 genes related to time in therapeutic range in patients with atrial fibrillation using warfarin
por: da Silveira, Maria Mariana Barros Melo, et al.
Publicado: (2019)

The role of interleukin-18 in the metabolic syndrome
por: Trøseid, Marius, et al.
Publicado: (2010)

Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis
por: Zhang, Jinhua, et al.
Publicado: (2016)

Enoxaparin-sodium/heparin/warfarin: Heparin-induced thrombocytopenia and elevated INR: case report
Publicado: (2021)

Determining INR Awareness of the Patients who Use Warfarin and Rates of Achieving the Target Dosage
por: Demir, Nazan, et al.
Publicado: (2020)

Extending INR testing intervals in warfarin patients at a multi-center anticoagulation clinic
por: Papala, Michelle, et al.
Publicado: (2021)

Hyper-responsiveness to warfarin in a young patient with the VKORC1 -1639GA/CYP2C9*1*46 genotype: a case report
por: Aldiban, Weam, et al.
Publicado: (2022)

Very Long Chain Marine n-3 Polyunsaturated Fatty Acids in Atherothrombotic Heart Disease. A Brief Review, with a Focus on Metabolic Effects
por: Arnesen, Harald, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sn7b5hhktgk4iu2l5lctkmkg95